Concurrent chemoradiotherapy plus immunotherapy for locally advanced non-small-cell lung cancer: clinical efficacy...

To evaluate the efficacy of concurrent chemoradiotherapy (CCRT) combined with immunotherapy (IT) for locally advanced non-small-cell lung cancer (LA-NSCLC). Short-term treatment outcomes during the two-year follow-up were recorded, and 2-year survival data were collected to analyze prognosis and identify factors affecting short-term outcome. Additionally, a predictive model was developed.

We conducted a retrospective analysis of 90 LA-NSCLC patients admitted between February 2018 and February 2020. Patients were grouped according to their treatment regimens: 45 patients treated with 4-6 cycles of CCRT followed by 1 year of Sintilimab therapy were assigned to the observation group, and 45 patients treated with cisplatin/carboplatin + albumin-bound paclitaxel for 4-6 cycles after CCRT were assigned to the control group. Short-term adverse reactions were recorded for both groups. Patients were followed up after 4-6 cycles of IT or chemotherapy, and short-term efficacy and toxicity were evaluated. During the 2-year follow-up, overall survival (OS) and progression-free survival (PFS) were recorded, and survival curves were plotted. The Cox proportional hazards model was used to identify factors influencing PFS in the observation group, and a predictive model was developed. The predictive value of relevant indicators for prognosis was assessed using receiver operating characteristic (ROC) curves.

The observation group showed superior short-term efficacy, with higher objective response rates (ORR) and disease control rates (DCR) compared to the control group (both P < 0.05). Regarding toxicity, the control group exhibited more severe adverse effects, particularly grade III and higher gastrointestinal reactions, leukopenia, thrombocytopenia, and anemia (all P < 0.05). The PFS was significantly higher in the observation group than that of the control group (P < 0.05). Additionally, the incidence of pneumonia was higher in the observation group, but it demonstrated better 2-year OS (P < 0.05). Cox multivariate analysis revealed that factors influencing PFS in the observation group included distant metastasis, tumor differentiation, platelet-to-lymphocyte ratio (PLR), and prealbumin (PAB). ROC analysis showed that the areas under the curve (AUC) for predicting prognosis based on PLR and PAB were 0.662 and 0.774, respectively, and the combined AUC of these indicators was 0.812.

CCRT combined with IT is an effective treatment for LA-NSCLC, improving survival outcomes. The predictive model developed may help assess prognosis and guide early clinical intervention. Attention should be given to pneumonia prevention and management during IT. Moreover, the combination of PLR and PAB enhances prognostic prediction for NSCLC patients undergoing CCRT plus IT.